MannKind (MNKD) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Financial and operational transformation

• Revenue has grown from $8 million to nearly $300 million, with no debt and $300 million in cash reserves.

• The company is positioned for significant pipeline developments and has transformed its financial health.

Afrezza clinical and regulatory updates

• Key data from the INHALE-3 adult study and pediatric studies are expected in Q4, focusing on improved dosing and outcomes.

• Updated dosing data may support a label update, initially targeting adults, with potential to extend to pediatric use.

• Label changes could address physician concerns about dosing and improve market adoption.

• Achieving a 10%+ pediatric market share could triple Afrezza revenue to $150 million annually.

• Filing for pediatric approval may occur in the first half of next year, pending FDA guidance.

Market dynamics and commercial strategy

• Safety perceptions remain the main barrier to broader physician adoption, despite a decade of positive safety data.

• New clinical data may renew interest from larger pharma partners, especially for ex-U.S. opportunities.

• Patient access is prioritized, with pricing strategies ensuring affordability and margin protection.

• Commercial infrastructure is maintained to support both Afrezza and upcoming orphan drug launches.